Liu Hao, project manager of Wuhan Shengda Kangcheng, debuts a photon therapy device on March 8. "We expect to get the registration certificate of medical devices in September, and mass production is expected within this year." , for example, liu hao said. This is an accelerated wound healing treatment instrument, a number of domestic hospitals have purchase intention.

Shengda Kangcheng, a state-level high-tech enterprise, focuses on the research and development of various kinds of wound medical consumables. Its customers cover more than 3,000 hospitals across the country, serving more than one million patients. Last September, its company headquarters moved from Beijing to Wuhan precision medicine Industrial base.

"The efficiency of administrative approval for medical devices is like our lifeline." Xiao Xiangzhong, general manager of Shengda Kangcheng, said that it takes more than 2 years on average for medical device products to get approval, which can be shortened to 1 year on average in Wuhan. With the help of the park, the company will have 3 products approved for market this year.

Wuhan Precision Medicine Industrial Base is a self-owned park owned by Hubei Liandou East Lake High-tech Group, with a scale of 230,000 square meters. It will be constructed in three phases and completed in 2023. It is estimated that more than 50 enterprises will settle in the base, with a total output value of 2 billion yuan and an annual growth rate of over 30% of total revenue.

At present, the first phase of the project has been delivered and incorporated, which has gathered high-quality enterprises such as Broad Pharmaceutical (China) Co., LTD., Wuhan Ibotek Biotechnology Co., LTD., Wuhan Kanglu Biotechnology Co., LTD.

The second phase, which is under construction, has also been fully booked, and 30% of the enterprises in the park have been expanded from other Hubei LiANTU parks. "Enterprises have once again chosen us, which represents a high recognition of the park's services and comprehensive strength." Donghu High-tech Group Wuhan regional company general manager He Dongling said.

Planning: Focus on the industrial cluster of subdivision

There is no doubt that the development of biological medicine has ushered in a huge tuyere. Media data show that since 2015, China's biomedicine market has been expanding, and with an annual growth rate of about 11%, leading the world, the market size is expected to exceed 500 billion yuan by 2025.

Centering on the biomedical industry, East Lake High-tech Group has been deeply engaged for many years, and the layout of the park has spread from Wuhan to the whole country. After accumulating rich industrial resources and experience, it will start to feed Hubei Province. In 2012, Optics Valley Bio-City cooperated with East Lake High-tech Group to develop Wuhan Optics Valley International bio-pharmaceutical Enterprise Accelerator, which became the first batch of market-based operation projects of Bio-City; In 2015, East Lake High-tech Group joined hands with Hangzhou Yuhang Economic and Technological Development Zone to successfully build Hangzhou biomedicine Accelerator and operate the only demonstration base of biomedicine industry in Zhejiang Province -- Zhejiang biomedicine Incubator. In 2019, the plan of Optical Valley South University Health Industrial Park was launched, and East Lake High-tech Group laid out East Lake High-tech International Health City. Relying on rich industrial resources and mature operational experience, it achieved the "four ones" of Optical Valley South University Health Industrial Park: The first batch of signing, the first to start construction, the first to complete the completion of the record, the first to complete the investment, once again to make a contribution to the construction of Wuhan trillion big health industry cluster.

In this process, the construction mode of East Lake High-tech Group industrial Park has been iterated and updated. "Along the way, we have faced opportunities, difficulties and choices. We have been thinking about what the big health industry should do. Should it only bring in big companies and good companies? Is it possible to include all biological industries?" After years of fighting the market wave, He Dongling has deeply realized the huge value behind industrial upgrading, which means the explosive all-round growth of high productivity, high tax and high added value of the industry.

As the domestic medical and health industry continues to grow, medical incubators and industrial parks have sprung up. However, a true precision medicine platform with a large ecosystem has been lacking until now.

"Ten years ago, we were already thinking that under the guidance of the hand of the market, industrial clusters would become a trend and then inevitably lead to segmentation." He Dongling believes that the evergreen tree of the future industrial park is bound to be the leader of a market segment.

It has become an important direction to promote the upgrading and transformation of the industry to cultivate the segmentation of the biomedical industry cluster and deepen the precision medical industry. "We see the development opportunities of the biomedical industry, actively embrace the resources of 100 billion biomedical industry, and are determined to build the most distinctive international bio-precision medicine industry gathering place." He Dongling's words are full of pride.

Power: Aim at the forefront of precision medicine

How to promote the development of precision medicine technology and promote the industrialization of enterprise research results in China? Wuhan precision Medicine Industrial base has become an important layout for East Lake High-tech Group to seize the emerging industrial highland.

As an innovative model and diagnosis and treatment technology that gathers the most cutting-edge scientific research results, the core content of precision medicine is personalized medicine, which collects genomics and other molecular information to provide patients with more accurate medical services.

For example, gene sequencing can find out the mutated genes of cancer, so as to quickly determine the correct drugs, save the time for patients to try various treatment methods, and improve the therapeutic effect. Genetic sequencing even requires only the patient's blood or saliva, eliminating the need for traditional pathological slides to reduce the damage to the patient's body during the diagnostic process.

Previously, Ms. Zhang, a resident of Wuchang, was hospitalized for cerebral infarction. She had a burning feeling in her stomach, nausea and vomiting after taking aspirin. Clinicians consider clopidogrel as an alternative treatment. Both clopidogrel and aspirin have anti-platelet aggregation and adhesion effects, but some patients are not suitable for aspirin, so clopidogrel can be used, such as Ms. Zhang. To determine the patient's tolerance to the drug, the hospital decided to conduct genetic testing. The sample of the patient was sent to the laboratory of Coxingrui, an enterprise in the park. The results showed that the patient could take the conventional dose of clopidogrel and achieved a good therapeutic effect.

"We not only provide enterprises with outstanding scientific research and management environment, through the complete industry chain for enterprises to create brand value and market profits, to meet the government to attract investment, such as taxes, promote urban economy prosperity of demand, also can inject new life and health industry development driving force for our country, to speed up the major disease prevention and control technology breakthrough, We will take the lead in the future development of medical and related industries."

In the final analysis, the ultimate goal of precision medicine is to realize individualized precision medicine and benefit everyone, so as to improve the health level of the whole population. In order to make precision medicine from scientific research to clinical application, so that the society and the public really enjoy the dividends brought by scientific and technological achievements, industrialization is the only way.

Future: To build a leading highland of scientific innovation in China

In order to cope with the ever-changing situation of technological innovation and increasingly fierce international technological competition, the Park chooses industry first between the immediate profits within reach and the greater profits brought by industrial clusters.

"The industrial chain of biomedicine is very long, and we want to choose companies that meet the government's needs and have excellent performance in paying taxes on output profits." Under the guidance and support of the local government, many parks of East Lake High-tech Group have jointly established an evaluation mechanism to strictly check the industrial attributes and tax levels of the enterprises to ensure the high quality of the enterprises in the park.

At the same time, considering the demand for capacity replacement and upgrading as well as the characteristics of biomedical enterprises, the park is still optimistic about enterprises with high technology content and great development potential, even though they have low profits at the present stage.

"After all, one of the biggest characteristics of biomedical enterprises is the rapid development. In five years, it is not uncommon to see enterprises whose output value has increased from about 20 million yuan to hundreds of millions yuan. Many enterprises in the park have seen their output value increase exponentially."

Aebotech is a global supplier of biological antibody and molecular enzyme reagent solutions. It settled in the park of East Lake High-tech Group in 2018, with an office area of 2,000 square meters. With the rapid development of the enterprise, last year, due to the expansion needs, Aebotech moved to the precision medicine industrial base, with an area of 26,000 square meters. Here, the research and development and production base of antibodies and molecular enzymes will be built.

In order to make enterprises can grow up better in the park, wuhan precision medical industry base in the optical valley biopolis has built excellent one-stop production, from the industrial chain of research and development, test, process, production, logistics, to the service chain products found, drug certificate services, financial services to manufacturing channels, which is based on industry research, enterprise services as the means, Integrate industrial chain resources and build industrial ecology.

"Wuhan precision Medicine Industrial Base will definitely become a national leading industrial park with core competitiveness." He Dongling said.